Pacira Pharma (PCRX) Tops Q4 EPS by 8c

Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.35, $0.08 better than the analyst estimate of $0.27. Revenue for the quarter came in at $61.8 million versus the consensus estimate of $62.1 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Ardagh Metal Packaging S.A. Q2 2026 Results and Investor Call Notification
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)